---
title: 'Funding Daily Summary: What Happened on October 4, 2026'
headline: Ai3Bio raises $48 million for immune-reset therapies
description: The startup’s first approach targets inflammatory T cells, with initial
  human tests possible next year.
url: https://thebench.bio/news/funding/2026-10-04
topic: funding
date: '2026-10-04'
covers:
- '2026-10-04'
date_published: '2026-10-05T00:00:22Z'
date_modified: '2026-10-05T00:00:22Z'
sources: 1
publisher: The Bench (thebench.bio)
---

# Funding Daily Summary: What Happened on October 4, 2026

**Ai3Bio raises $48 million for immune-reset therapies**

The startup’s first approach targets inflammatory T cells, with initial human tests possible next year.

## Today in brief

Ai3Bio emerged from stealth with a $48 million Series A to advance its immune-reset therapy pipeline. [1] Its first intended target is Th17 cells, and initial human tests could begin next year. [1]

## Also worth knowing

- Ai3Bio’s antibody-guided lipid nanoparticles are designed to carry mRNA into target cells and activate the cGAS-STING pathway. Co-founder Jonathan Kagan said animal studies depleted inflammatory T cells, including in monkeys’ spleens and lymph nodes, but durability has not been demonstrated in people. [1]

## The day in numbers

- **$48 million**: Ai3Bio’s Series A, led by founding investors Ziff Capital Partners and UPMC Enterprises, with Cockrell Interests and Tanis Ventures also participating. [1]

## Sources

1. [Immunology Startup ai3Bio Aims to Redefine What It Means to Reset the Immune System](<https://medcitynews.com/2026/10/immune-reset-startup-ai3bio-immunology-inflammation-autoimmune-liver-disease-t-cell-th17-il-17-cgas-sting/>), MedCity News, 2026-10-04

---

The Bench wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://medcitynews.com/2026/10/immune-reset-startup-ai3bio-immunology-inflammation-autoimmune-liver-disease-t-cell-th17-il-17-cgas-sting/>